His diabetes had previously been managed with metformin alone; however, in response to rising glycohemoglobin (HbA1c) levels, peaking at 7.7%, and worsening proteinuria, he was recently initiated on empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i). Here, SLC5A2 is linked to diabetes mellitus.